GRI Bio, Inc. (GRI) stock
GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.12+0.00 (0.00%)
Close on Nov 20, 2026Market cap $2.45MP/E –Yield –
GRI Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
GRI Bio's free cash flow for the twelve months ending Dec 31, 2024 was -$8.61M. For fiscal 2025 it was -$10.19M. The highest annual figure on record is -$1.09M in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.19M | – |
| FY2024 | Dec 31, 2024 | -$8.61M | – |
| FY2023 | Dec 31, 2023 | -$9.00M | – |
| FY2022 | Dec 31, 2022 | -$1.09M | – |
| FY2021 | Dec 31, 2021 | -$8.31M | – |
| FY2020 | Dec 31, 2020 | -$3.71M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$2.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.56M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.31M | – |
| Q4 FY2022 | Dec 31, 2022 | -$847.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$125.00K | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.29M | – |
| Q4 FY2020 | Dec 31, 2020 | -$808.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.07M | – |
| Q1 FY2020 | Mar 31, 2020 | -$768.00K | – |
See a number that looks wrong?